Letermovir Resistance in Hematopoietic Stem Cell Transplant Recipients: The Risks Associated with Cytomegalovirus Prophylaxis

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2019 Dec 1

PMID 31784759

Citations 1

Authors

Scott H James

Affiliations

Soon will be listed here.

Citing Articles

Small Molecules-Prospective Novel HCMV Inhibitors.

Bogner E, Egorova A, Makarov V Viruses. 2021; 13(3).

PMID: 33809292 PMC: 8000834. DOI: 10.3390/v13030474.

References

Rubin R . Preemptive therapy in immunocompromised hosts. N Engl J Med. 1991; 324(15):1057-9. DOI: 10.1056/NEJM199104113241509. View

Gentry B, Bogner E, Drach J . Targeting the terminase: An important step forward in the treatment and prophylaxis of human cytomegalovirus infections. Antiviral Res. 2018; 161:116-124. DOI: 10.1016/j.antiviral.2018.11.005. View

Piret J, Goyette N, Boivin G . Drug Susceptibility and Replicative Capacity of Multidrug-Resistant Recombinant Human Cytomegalovirus Harboring Mutations in and Genes. Antimicrob Agents Chemother. 2017; 61(11). PMC: 5655094. DOI: 10.1128/AAC.01044-17. View

Cherrier L, Nasar A, Goodlet K, Nailor M, Tokman S, Chou S . Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. Am J Transplant. 2018; 18(12):3060-3064. PMC: 6263820. DOI: 10.1111/ajt.15135. View

Douglas C, Barnard R, Holder D, Leavitt R, Levitan D, Maguire M . Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients. J Infect Dis. 2019; 221(7):1117-1126. PMC: 7075417. DOI: 10.1093/infdis/jiz577. View

Chou S . Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. Antimicrob Agents Chemother. 2015; 59(10):6588-93. PMC: 4576131. DOI: 10.1128/AAC.01623-15. View

Green M, Leisenring W, Xie H, Mast T, Cui Y, Sandmaier B . Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol. 2016; 3(3):e119-27. PMC: 4914379. DOI: 10.1016/S2352-3026(15)00289-6. View

Teira P, Battiwalla M, Ramanathan M, Barrett A, Ahn K, Chen M . Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016; 127(20):2427-38. PMC: 4874224. DOI: 10.1182/blood-2015-11-679639. View

Chou S, Satterwhite L, Ercolani R . New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by Exposure to Letermovir and Ganciclovir. Antimicrob Agents Chemother. 2018; 62(9). PMC: 6125535. DOI: 10.1128/AAC.00922-18. View

10.

Chou S . A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. Antiviral Res. 2017; 148:1-4. PMC: 5687998. DOI: 10.1016/j.antiviral.2017.10.019. View

11.

Frietsch J, Michel D, Stamminger T, Hunstig F, Birndt S, Schnetzke U . In Vivo Emergence of UL56 C325Y Cytomegalovirus Resistance to Letermovir in a Patient with Acute Myeloid Leukemia after Hematopoietic Cell Transplantation. Mediterr J Hematol Infect Dis. 2019; 11(1):e2019001. PMC: 6328044. DOI: 10.4084/MJHID.2019.001. View

12.

Marty F, Ljungman P, Chemaly R, Maertens J, Dadwal S, Duarte R . Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. N Engl J Med. 2017; 377(25):2433-2444. DOI: 10.1056/NEJMoa1706640. View

13.

Goldner T, Hempel C, Ruebsamen-Schaeff H, Zimmermann H, Lischka P . Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. Antimicrob Agents Chemother. 2013; 58(1):610-3. PMC: 3910730. DOI: 10.1128/AAC.01794-13. View